Biologic Therapy Companies

AbbVie (US) Announced positive Phase 3 trial results for Skyrizi® (risankizumab) in July 2023, demonstrating its efficacy in treating plaque psoriasis, highlighting potential applications for other inflammatory conditions.

Roche (Switzerland) Received FDA approval for Tecentriq® (atezolizumab) in combination with Abraxane® (nab-paclitaxel) in September 2023 for the treatment of non-small cell lung cancer, offering another option for advanced stages.

Regeneron Pharmaceuticals (US) Launched Dupixent® (dupilumab) for the treatment of atopic dermatitis in adolescents in June 2023, expanding its reach to address childhood conditions beyond adult populations.

Novartis (Switzerland) Partnered with Amylyx Inc. (US) in October 2023 to develop and commercialize Amylyx's investigational gene therapy for the treatment of amyotrophic lateral sclerosis (ALS), showcasing collaboration in emerging areas like gene therapy.

BioMarin Pharmaceutical Received FDA approval for Vimizim® (elosulfase alfa) in August 2023 for the treatment of Morquio A syndrome, demonstrating commitment to rare disease therapeutics and fulfilling unmet medical needs.

List of Biologic Therapy Key Companies in the Market

• Samsung Biologics (South Korea)


• Amgen Inc (US)


• Novo Nordisk A/S (Denmark)


• Sanofi (France)


• Johnson & Johnson Services, Inc (US)


• Celltrion Healthcare Co., Ltd (South Korea)


• Bristol-Myers Squibb Company (US)


• Eli Lilly and Company (US)


• Hoffmann La-Roche Ltd (Switzerland)


• Aeglea BioTherapuetics (US)